Horizon receives authorization to increase Tepezza production

Horizon Therapeutics has received a prior approval supplement for its previously approved biologics license application so that it can manufacture more Tepezza for the treatment of thyroid eye disease, according to a press release.
“We are pleased that patients who have had to struggle with the debilitating effects of thyroid eye disease will soon have access again to Tepezza, the only FDA-approved medicine to treat this rare disease, and we appreciate their patience and understanding during this unfortunate disruption,” Tim Walbert, chairman, president and CEO of Horizon, said in

Full Story →